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ther PCOS or EC were recruited into a cross-sectional study at the Nottingham
UniversityHospital,UK.ForRNAsequencing,representative individualendometrial
biopsies were obtained fromwomenwith EC, PCOS and a woman unaffected by
PCOSorEC.Expressionof a subsetofdifferentiallyexpressedgenes identifiedby
RNAsequencing,includingNAD(P)Hquinonedehydrogenase1(NQO1),wasvalidated
byquantitativereversetranscriptasePCRvalidation(n=76)andinthecancergenome
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1  | INTRODUCTION
Endometrial cancer (EC) is themost common gynaecological can-
ceraffectingwomenintheUnitedStates,withanestimated60050
newcasesin2016.1TheincidenceofEChasincreasedbyover65%
since the late 1970s correlating with rising incidence of obesity
and increased longevity.2,3 EC is usually treated by hysterectomy,
butsurgerycarriesincreasedriskinobesewomenandrenderspre-
menopausalwomen infertile. Inaddition to itsnegative impacton
quality of life, EC poses a significant economic burden on health
services.
Polycysticovarysyndrome(PCOS) is thecommonest femaleen-






The exactmechanisms that predisposePCOSwomen to EC re-
main unknown. Current hypotheses include a link between obesity
and elevated oestrogen levels, inflammation, type 2 diabetes and









standing of mechanisms linking PCOS and EC. To our knowledge,
comparative transcriptomic, proteomic or metabolomic studies of









patients (N=76)were recruited into to a cross-sectional study con-
ductedwithin the division of Obstetrics and Gynaecology and Child
Health, at Nottingham University Hospital in the United Kingdom.
Participantswereprospectively recruited fromJuly2013 toFebruary
2014. Research ethics approval was obtained from the National
Research Ethics Service, East Midlands-Northampton committee 
(13/EM/0119)priortocommencementofrecruitment.Theprojectwas
also reviewed and approved by the relevant local ethics committees
attheUniversityofNottingham.TheHelsinkiDeclarationwasstrictly





stored immediately in RNAlater (Sigma-Aldrich, Gillingham, UK). For






ing total hysterectomy (by laparotomy or laparoscopically) who had
not received previous neo-adjuvant chemo- or radiotherapy.Women
were excluded from the study for prior history of papillary serous
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adenocarcinomaormetachronouscancersoftheovary,endometrium
orcervix.ThePCOScohortwasdefinedusingtheRotterdamEuropean
















2.2 | RNA sequencing (RNAseq) and quantitative 
reverse transcriptase PCR (qRT- PCR) analysis of 
patient endometrial samples
TotalRNAwasisolatedusinganRNeasyextractionkit,withon-column
DNAse digestion (Qiagen, Manchester, UK). RNA quality (RIN>7)








Paired end raw reads (fastq format)were quality- and adapter-
filtered using the Trim-galore wrapper for FastQC and cutadapt
(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/).




















Control (n = 25) PCOS (n = 26)
Endometrial cancer 
(n = 25) P value
Age(years);Mean(SD) 45.96(13.34) 31.88(5.975) 62.64(11.10) <.0001*
BMI(Kg/m2);Mean(SD) 29.27(2.467) 29.60(3.116) 33.12(5.959) .0021*
WHCratio;Mean(SD) 88.56(3.241) 88.5(3.992) 96.86(12.99) .0003*
SystolicBP(mmHg);Mean(SD) 135.9(8.729) 134.1(7.591) 148.2(11.42) <.0001*
DiastolicBP(mmHg);Mean(SD) 81.88(7.563) 83.35(7.746) 84.80(7.455) .4012
Fastinginsulin;Mean(SD) 13.47(6.002) 20.04(31.79) 18.3(16.26) .5199
Fastingglucose;Mean(SD) 4.844(0.4788) 5.142(0.8363) 6.4(1.649) <.0001*
HOMA-IR;Mean(SD) 0.1809(0.1065) 0.2617(0.4405) 0.3139(0.3766) .3871
LDL;Mean(SD) 2.820(0.8539) 2.738(0.8174) 2.632(0.9919) .7561
HDL;Mean(SD) 1.5(0.3136) 1.415(0.2664) 1.648(0.3754) .0381*
TG;Mean(SD) 1.344(0.6752) 1.373(0.4609) 1.54(0.5694) .4305
Totalcholesterol;Mean(SD) 5.004(0.9654) 1.373(0.4609) 1.54(0.5694) .5293
FSH;Mean(SD) 17.88(24.81) 5.008(2.788) 49.01(20.83) <.0001*
LH;Mean(SD) 12.95(12.04) 12.31(11.08) 28.64(13.08) <.0001*
Testosterone;Mean(SD) 1.516(0.6309) 2.846(0.7089) 1.492(0.8684) <.0001*
Oestradiol;Mean(SD) 414.5(655.8) 331.9(261.3) 96.72(55.39) .0204*
Progesterone;Mean(SD) 6.448(15.37) 11.2(14.54) 1.28(0.5292) .0192*
SHBG;Mean(SD) 55.36(38.65) 34.46(14.03) 50.6(17.01) .0120*
*Pvalue<.5issignificantareindicated.
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were as follows: β-actin: Hs01060665_g1;NQO1: Hs02512143_s1.









at StMary’s Hospital inManchester between 2011 and 2013, and
whoprovidedwritten,informedconsentfortheirtumoursamplesto
bestoredintheBRCBiobankandusedforfutureresearch.Afurther

















































3.1 | Patient demographics for samples used for the 




42)wereused for theRNAsequencingexperiments.RNAseq iden-
tified differentially expressed genes (using standard criteria of fold




was most similar to the control obese woman (Figure1). Of these
genes,94genesweredifferentiallyexpressedinbothECandPCOS
relative to control endometrium (Table S1). Specifically, 12 genes
werehigherand82werelowerinPCOSandECspecimensrelativeto
controlendometrium(TableS1,S2).
In the qRT-PCR validation cohort, the BMIs of women with EC
(33.12±5.959kg/m2), PCOS (31.88±5.975kg/m2) and controls
(29.27±2.467kg/m2) were not significantly different. PCOSwomen






target p53 and another exemplar gene identified by RNAseq, GJB2, 
(Figure S1)was significantly increased (P <.05) in endometrial speci-
mensfromwomenwithPCOS(n=25)andEC(n=25)ascomparedto
control,unaffectedwomen (n=25).Wenextexaminedexpressionof
these94genes inpatientswithECusing thecancergenomeatlas.17 
Of these94 genes, 14 genes (NQO1, SLPI, GJB2, DNAJC15, S100A8, 












3.2 | Immunohistochemistry validating the role of 
NQO1 in EC
The Manchester EC patient demographics and clinicopathological
features are shown (Table2). The control womenwere postmeno-
pausalwithhistologically normal endometriumandunderwenthys-
terectomyforgenitalprolapse.Histologicallynormalpostmenopausal
endometrium did not expressNQO1 (Figure2). In EC, therewas a
statistically significant association between high NQO1 expression












Known risk factors forEC include increasingage,polycysticovary
syndrome(PCOS),obesityandtype2diabetes.18-21Weandothers
haveidentifiedalteredSREBP1,11andinsulinsignallinginendome-
trial specimens from women with PCOS or EC.10,22 Anovulatory
menstrualcycles,commonlyfoundinPCOSwomen,havealsobeen
linkedwithEC.23Themechanismsarethoughttoinvolveastateof
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thenaturalsheddingofabnormalendometrialcells.Acommonsys-




in theendometriumofwomenwithPCOS thatmaypredispose to
EC. Indeed, while previous gene expression studies have inves-
tigated PCOS24 and EC,25 the exact mechanisms that predispose











NQO1 has an established role in the endometrium.26 NQO1 
encodes NAD(P)H:quinone oxidoreductase 1 in detoxification
pathways27-29andhasbeen reported toactivatespecificquinone-
derivedpharmaceuticalsincludingmitomycinCandapaziquone.30,31 
NQO1 also acts to protect the p53 tumour suppressor protein,
and many other proteins involved in proliferation from proteaso-
mal degradation.32 Interestingly, missense variants in NQO1 are 
implicated inmany cancer types33-35 andmore recently, increased
















68(58-74) 67(56-72) 72.5(63.3-77.8) .007**
MedianBMIatdiagnosis
kg/m2(IQR)
30.1(26.1-37.1) 30.1(26.0-39.1) 29.6(26.3-35.2) .622
Diabetic,n(%)
No 71(78.0) 43(81.1) 28(73.7) .629
Yes 20(22.0) 10(18.9) 10(26.3)
Histologicalgrade,n(%)
1 23(25.3) 15(28.3) 8(21.1) .164
2 20(22.0) 12(22.6) 8(21.1)
3 48(52.7) 26(49.1) 22(57.9)
FIGO(2009)stage,n(%)
1 59(64.8) 34(64.2) 25(65.8) .115
2 12(13.2) 9(17.0) 3(7.9)
3 18(19.8) 9(17.0) 9(23.7)
4 2(2.2) 1(1.9) 1(2.6)
Histologicaltype,n(%)
Endometrioid 48(52.7) 31(58.4) 17(44.7) .100
Nonendometrioid 43(47.3) 22(41.5) 21(55.3)
Lymphovascularspaceinvasion,n(%)
Absent 50(53.8) 32(60.4) 18(47.4) .356
Present 38(41.8) 18(34.0) 20(52.6)
Missingdata 3(3.3) 3(5.7) 0(0)
Depthofmyometrialinvasion,n(%)
<50% 51(56.0) 31(58.5) 20(52.6) .412
≥50% 40(44.0) 22(41.5) 18(47.4)
Anyadjuvanttreatment,n(%)
No 37(40.7) 23(43.4) 14(36.8) .366
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selectivelywithinmalignanttissuemaybeanattractivetherapeutic
approach.38ConsistentwiththisNQO1nullmicearemoresensitive
to chemical induced carcinogenesis32 and NQO1 plays an essen-
tial role in oncogene-induced senescence. However, the associa-
tion of overexpression ofNQO1with poorer outcomes in certain





2).NQO1expression is regulatedby theoestrogen receptor-α (ERα/





















that resembles EC. It is possible such changes in gene expression
contributetothe increasedriskofEC inwomenwithPCOS.NQO1
representsapotentialtherapeutictargetinEC.NQO1isinhibitedby
dicoumarol, andmore specificnext-generationNQO1-inhibitors are
now available (Figure3).44Therefore, the preclinical testing of such
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